India Pharma Outlook Team | Monday, 10 August 2026
The wellness market in India enters a transformative phase as Warburg Pincus moves to acquire Universal Nutriscience.
This highlights rising investor confidence in the wellness market and the rapid expansion of the nutraceutical industry in India.
The deal reflects strong momentum in preventive healthcare growth, driven by consumer demand for supplements and lifestyle products.
Existing investors, including Kedaara Capital, will exit, marking one of the most notable private equity healthcare investment deals in India’s consumer health segment.
The wellness market continues to attract global investors as Warburg Pincus leads the race to acquire Universal Nutriscience. The firm outpaced bidders such as ChrysCapital, Procter & Gamble, TA Associates, and Haleon to secure the deal. This acquisition marks Warburg’s fourth healthcare investment in India within a short span, reinforcing its aggressive expansion strategy.
The firm aims to build a scalable healthcare and pharmaceutical platform by integrating complementary businesses across nutraceuticals, specialty therapies, and branded formulations. The deal aligns with rising private equity healthcare investment focused on preventive healthcare growth.
Also Read: Building Resilient QMS in Global Pharma Manufacturing
Universal Nutriscience has emerged as a key player in the wellness market with its portfolio of nutraceutical brands acquired from Sanofi India for Rs 587 crore. The company operates leading products such as Seacod, ECod, CoQ, Primosa, and Collaflex, supported by a strong marketing and distribution network.
It expects revenue to reach Rs 340 crore with EBITDA of around Rs 110 crore in FY27, reflecting robust financial growth. This performance strengthens its position in the nutraceutical industry in India and drives investor interest in high-growth consumer health platforms.
The wellness market is witnessing a structural shift as this acquisition sets a new benchmark for large-scale deals in the nutraceutical industry India. Warburg Pincus focuses on building a multi-asset healthcare platform by acquiring complementary businesses across women’s health, orthopaedics, and specialty therapies.
This strategy reflects a broader trend where investors move beyond traditional pharmaceuticals into preventive healthcare growth segments. The deal also signals increasing consolidation, as companies with strong brands and distribution networks attract premium valuations and global capital.
The wellness market in India continues to expand rapidly, supported by rising health awareness, lifestyle disease concerns, and increased adoption of supplements. The nutraceutical industry in India, valued at USD 29–30 billion in 2024, is expected to grow to USD 55–57 billion by 2030, reflecting a CAGR of 10.5 per cent.
Digital platforms, e-commerce expansion, and supportive policies further accelerate growth. This environment strengthens private equity healthcare investment and positions India as a major hub for consumer health and wellness innovation.
